Adel Michael Joins E-Z-EM Board of Directors

  
    
  
  
    
      E-Z-EM, Inc., (AMEX:EZM) today announced that Adel Michael was 
      elected to its Board of Directors on May 4, 2007.
    
    
      Mr. Michael, 63, is an experienced senior executive with a broad 
      background in all aspects of business development and management. Over a 
      distinguished thirty-five year career, he has held leadership positions 
      with global responsibilities in finance, manufacturing, legal and IT 
      systems, and general management. He also has extensive expertise in 
      strategic acquisitions and divestitures, budgeting and planning, 
      financial analysis and controls, profit modeling, international 
      business, treasury and taxes.
    
    
      Mr. Michael recently served as the Vice Chairman of the Board and Chief 
      Financial Officer of Mentor Corporation (NYSE:MNT), a leading supplier 
      of Medical Aesthetics and Urology products for the global market. Prior 
      to Mentor he was Senior Vice President and Chief Financial Officer of 
      Getz Brothers and Co. Inc., San Francisco, CA. a subsidiary of the 
      Marmon Group Chicago, Il. Marmon is a major international conglomerate 
      of manufacturing and services worldwide with annual revenues of over $7 
      billion and employing 40,000 employees, where Michael also served as a 
      Corporate Controller. Michael was the Controller of Amphenol 
      Corporation, a subsidiary of Allied / Signal Corporation in Toronto, 
      Canada and Chicago, IL.
    
    
      Commenting on the announcement, Paul S. Echenberg, Chairman of E-Z-EM, 
      Inc., said, “The election of Adel to our board 
      is a reflection of our desire to add new perspective and expertise to 
      our board. Adel brings to us a wealth of experience and knowledge in 
      strategic business development, and we look forward to the benefits of 
      his guidance.”
    
    
      About E-Z-EM, Inc.
    
    
      E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal 
      radiology. The Company is the developer of VoLumen®, 
      the next generation low density barium sulfate suspension for use as an 
      oral contrast in Multidetector CT (MDCT) and Positron Emission 
      Tomography (PET/CT) studies. The Company also offers Empower® 
      -- the only family of CT injectors on the market with patented EDA™ 
      technology that can help detect contrast extravasation -- and offers a 
      complete product set for the virtual colonoscopy practitioner. This 
      product line consists of virtual colonoscopy hardware, software, 
      nutritional prep kits and bowel cleaners, tagging agents and a carbon 
      dioxide colon insufflation system. The Company is also the exclusive 
      world-wide manufacturer and marketer of RSDL for first-responder 
      organizations and military services. RSDL is a patented, broad-spectrum 
      liquid chemical warfare (CW) agent decontaminant, that neutralizes or 
      removes chemical agents from skin on contact, leaving a non-toxic 
      residue that can be rinsed off with water.
    
    
      The statements made in this document contain certain forward-looking 
      statements. Words such as “expects,” 
      “intends,” “anticipates,” 
      “plans,” “believes,” 
      “seeks,” “estimates” 
      or variations of such words and similar expressions, are intended to 
      identify such forward-looking statements. The forward-looking statements 
      contained in this release may involve numerous risks and uncertainties, 
      known and unknown, beyond the Company’s 
      control. Such risks and uncertainties include: to develop its products, 
      continued market acceptance and sales of VoLumen®, 
      future actions by the FDA or other regulatory agencies, overall economic 
      conditions, general market conditions, as well as the risk factors 
      listed from time to time in the SEC filings of E-Z-EM, Inc., including 
      but not limited to its Form 10-Q for the quarter ended March 3, 2007 and 
      its Annual Report on Form 10-K for the fiscal year ended June 3, 2006. 
      Consequently, actual future results may differ materially from the 
      anticipated results expressed in the forward-looking statements, and 
      investors are cautioned not to place undue reliance on the 
      forward-looking statements included in this release.